Celcuity Completes NDA Submission To FDA For Gedatolisib In Breast Cancer

Celcuity said it has submitted an NDA to the FDA under the Real‑Time Oncology Review program for gedatolisib in HR+/HER2-/PIK3CA wild‑type breast cancer; the drug holds Breakthrough Therapy and Fast Track designations. In the VIKTORIA‑1 phase 3 PIK3CA wild‑type cohort, gedatolisib plus fulvestrant and palbociclib cut risk of progression or death by 76% versus fulvestrant alone (median PFS 9.3 vs 2.0 months), while gedatolisib plus fulvestrant reduced risk by 67% (median PFS 7.4 vs 2.0 months); gedatolisib is a multi‑target PI3K/AKT/mTOR inhibitor designed to limit adaptive pathway reactivation. Celcuity has completed enrollment of the PIK3CA‑mutant cohort with topline data due late Q1–Q2 2026, is running VIKTORIA‑2 and a prostate cancer combo trial, and the stock recently closed at $92.23 (down 0.49%).

Analysis

Celcuity announced submission of a New Drug Application (NDA) to the FDA for gedatolisib in HR+/HER2-/PIK3CA wild-type breast cancer under the Real-Time Oncology Review (RTOR) pathway; gedatolisib has Breakthrough Therapy and Fast Track designations which can materially shorten review timelines. The company highlighted Phase 3 VIKTORIA-1 PIK3CA wild-type cohort results where the gedatolisib triplet (gedatolisib + fulvestrant + palbociclib) reduced risk of progression or death by 76% with median PFS of 9.3 months versus 2.0 months for fulvestrant alone, and the gedatolisib doublet reduced risk by 67% with median PFS 7.4 versus 2.0 months. Gedatolisib is positioned as a multi-target PI3K/AKT/mTOR inhibitor designed to block four Class I PI3K isoforms plus mTORC1/2 to limit adaptive pathway reactivation, and preclinical data show comparable potency in PIK3CA-mutant and wild-type cells. Celcuity has completed enrollment of the PIK3CA-mutant cohort with topline data expected late Q1–Q2 2026, is running VIKTORIA-2 and a mCRPC combo (CELC-G-201), and the stock recently closed at $92.23 (52-week range $7.57–$96.07); key near-term risks remain FDA review outcome, detailed safety data, and confirmatory mutant-cohort results.

Key Decisions for Investors

• Consider a selective long position ahead of FDA review given RTOR submission and strong PIK3CA wild-type Phase 3 efficacy, but size positions conservatively to reflect binary regulatory risk
• Monitor FDA communications and published safety/tolerability data closely and be prepared to trim exposure if safety signals or label restrictions emerge
• Watch topline data for the PIK3CA-mutant cohort due late Q1–Q2 2026 and enrollment progress in VIKTORIA-2 as catalysts that could materially re-rate the stock
• Given the stock is trading near its year-high, use protective hedges or limit order entries to manage downside if approval timing or outcomes deviate from current expectations